Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CCN001
MIFTS: 50

Cocaine Dependence

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cocaine Dependence

About this section

MalaCards integrated aliases for Cocaine Dependence:

Name: Cocaine Dependence 12 77 56 15 17 74

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:9975
ICD9CM 36 304.2 304.20
MeSH 45 D019970
NCIt 51 C34492
SNOMED-CT 69 31956009
ICD10 34 F14.2
UMLS 74 C0600427
Sources

Summaries for Cocaine Dependence

About this section
Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to personality disorder and antisocial personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Cocaine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 77 Cocaine dependence is a psychological desire to use cocaine regularly. Cocaine overdose may result in... more...

Sources

Related Diseases for Cocaine Dependence

About this section

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 personality disorder 30.9 DRD2 SLC6A3 SLC6A4
2 antisocial personality disorder 30.7 DRD2 SLC6A3 SLC6A4
3 psychotic disorder 30.6 DRD1 DRD2 DRD3 SLC6A3 SLC6A4
4 bipolar disorder 30.4 DRD2 DRD3 SLC6A3 SLC6A4
5 alexithymia 30.2 DRD2 SLC6A4
6 social phobia 30.0 DRD2 SLC6A4
7 smoking as a quantitative trait locus 3 30.0 CHRNA3 CHRNA5
8 substance abuse 29.9 DBH DRD2 DRD3 SLC6A3 SLC6A4
9 cocaine abuse 29.9 DBH DRD2 SLC6A3 SLC6A4
10 schizoaffective disorder 29.9 DRD2 DRD3 SLC6A4
11 heroin dependence 29.8 DRD2 OPRM1 PDYN
12 mood disorder 29.6 DRD2 DRD3 POMC SLC6A4
13 pathological gambling 29.5 DRD1 DRD2 DRD3 SLC6A3 SLC6A4
14 major depressive disorder 29.4 DRD2 DRD3 POMC SLC6A3 SLC6A4
15 schizophrenia 29.4 DBH DRD1 DRD2 DRD3 SLC6A3 SLC6A4
16 alcohol abuse 29.2 DRD1 DRD2 DRD3 SLC6A4
17 attention deficit-hyperactivity disorder 28.9 DBH DRD1 DRD2 DRD3 OPRM1 SLC6A3
18 obsessive-compulsive disorder 28.7 DRD1 DRD2 DRD3 PDYN SLC6A3 SLC6A4
19 tobacco addiction 28.5 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1 SLC6A3
20 drug dependence 28.1 CHRNB3 DRD2 DRD3 OPRK1 OPRM1 PDYN
21 alcohol dependence 28.0 DBH DRD1 DRD2 DRD3 OPRK1 OPRM1
22 cocaine intoxication 11.2
23 tic disorder 10.4 DRD2 SLC6A3
24 polysubstance abuse 10.3 DRD2 DRD3
25 delusional disorder 10.3 DRD2 DRD3
26 tardive dyskinesia 10.3 DRD2 DRD3
27 impulse control disorder 10.3 DRD2 DRD3
28 depression 10.3
29 periodic limb movement disorder 10.3 DRD2 SLC6A4
30 striatonigral degeneration 10.3 DRD2 SLC6A3
31 premature ejaculation 10.3 SLC6A3 SLC6A4
32 alcohol-induced mental disorder 10.2 DRD2 SLC6A3 SLC6A4
33 alcoholic psychosis 10.2 DRD2 SLC6A3 SLC6A4
34 restless legs syndrome 10.2 DRD2 DRD3 SLC6A3
35 cutaneous solitary mastocytoma 10.2 PDYN POMC
36 movement disease 10.2 DRD2 DRD3 SLC6A3
37 functioning pituitary adenoma 10.2 DRD2 POMC
38 migraine without aura 10.2 DRD2 DRD3 SLC6A4
39 stuttering 10.2 DBH DRD2 SLC6A3
40 phobic disorder 10.2 OPRK1 SLC6A4
41 multiple system atrophy 1 10.2 DBH DRD2 SLC6A3
42 gilles de la tourette syndrome 10.2 DBH DRD2 SLC6A3
43 migraine with aura 10.2 DBH DRD2 SLC6A4
44 neonatal abstinence syndrome 10.1 OPRK1 OPRM1
45 opioid abuse 10.1 DRD2 OPRM1 PDYN
46 retrograde amnesia 10.1 PDYN POMC SLC6A4
47 pol iii-related leukodystrophies 10.1
48 brunner syndrome 10.1 DBH SLC6A4
49 agoraphobia 10.1 OPRK1 SLC6A4
50 withdrawal disorder 10.0 OPRM1 PDYN POMC

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence
Sources

Symptoms & Phenotypes for Cocaine Dependence

About this section

MGI Mouse Phenotypes related to Cocaine Dependence:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 CHRNA3 CHRNA5 CHRNB3 DBH DRD1 DRD2
2 growth/size/body region MP:0005378 10.02 CHRNA3 DBH DRD1 DRD2 DRD3 OPRM1
3 adipose tissue MP:0005375 10 DBH DRD1 DRD2 DRD3 OPRM1 PDYN
4 homeostasis/metabolism MP:0005376 10 CHRNA3 DBH DRD1 DRD2 DRD3 OPRK1
5 digestive/alimentary MP:0005381 9.95 CHRNA3 DRD1 DRD2 DRD3 OPRK1 OPRM1
6 endocrine/exocrine gland MP:0005379 9.91 DBH DRD2 OPRK1 OPRM1 POMC SLC6A3
7 integument MP:0010771 9.81 DBH DRD1 DRD2 OPRK1 OPRM1 PDYN
8 mortality/aging MP:0010768 9.61 CHRNA3 DBH DRD1 DRD2 DRD3 OPRM1
9 nervous system MP:0003631 9.4 CHRNA3 CHRNA5 DBH DRD1 DRD2 DRD3
Sources

Drugs & Therapeutics for Cocaine Dependence

About this section

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 446220 5760
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
3
Biperiden Approved, Investigational Phase 4,Phase 3,Phase 2 514-65-8 2381
4
Caffeine Approved Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
5
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
6
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 64-17-5 702
7
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
8
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
9
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
10
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
11
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
12
Methamphetamine Approved, Illicit Phase 4,Not Applicable 537-46-2 10836
13
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 300-62-9 3007 5826
14
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
15
Choline Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 62-49-7 305
16
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 1,Early Phase 1 56-86-0 33032
17
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable 7440-70-2 271
18 Biperiden lactate Phase 4,Phase 3,Phase 2
19 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
23 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Purinergic P1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
34 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antioxidants Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Expectorants Phase 4,Phase 2,Phase 1,Early Phase 1
39 Free Radical Scavengers Phase 4,Phase 2,Phase 1,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
42 Antidotes Phase 4,Phase 2,Phase 1,Early Phase 1
43 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2
44 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 N-monoacetylcystine Phase 4,Phase 2,Phase 1,Early Phase 1
46 Antiviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
48 Tranquilizing Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 343)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
3 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
4 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
5 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
6 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
7 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
8 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4 quetiapine
9 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine
10 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
11 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
12 Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use Recruiting NCT02927236 Phase 4
13 A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
14 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
15 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
16 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
17 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
18 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
19 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3 Selegiline
20 Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
21 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
22 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3 Pergolide
23 Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
24 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3 Naltrexone;Placebo
25 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
26 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
27 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
28 Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
29 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
30 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
31 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
32 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
33 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3 Nefazodone
34 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
35 Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
36 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
37 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
38 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
39 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
40 Study of the Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence Unknown status NCT01397266 Phase 2
41 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
42 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
43 Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Unknown status NCT01259362 Phase 2
44 Repetitive Transcranial Magnetic Stimulation in Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
45 Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Unknown status NCT01929343 Phase 2 lidocaine following cue-induced craving;lidocaine following neutral stimulus;saline
46 N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder Unknown status NCT01172275 Phase 2 N-Acetylcysteine;Placebo
47 Psychopharmacology for Cocaine Dependence - Buspirone Completed NCT01267292 Phase 2 Buspirone;Placebo for Buspirone;Methylphenidate;Placebo for Methylphenidate
48 Brain Function and Structure in Cocaine Dependence Completed NCT02080832 Phase 2 Citalopram;Placebo
49 Pharmacogenetics of Doxazosin for Cocaine Dependence Completed NCT01145183 Phase 2 Doxazosin;Placebo
50 Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence Completed NCT01486810 Phase 1, Phase 2 Lisdexamfetamine

Search NIH Clinical Center for Cocaine Dependence

Sources

Genetic Tests for Cocaine Dependence

About this section
Sources

Anatomical Context for Cocaine Dependence

About this section

MalaCards organs/tissues related to Cocaine Dependence:

42
Brain, Heart, Cortex, Pituitary, Prefrontal Cortex, Testes, Prostate
Sources

Publications for Cocaine Dependence

About this section

Articles related to Cocaine Dependence:

(show top 50) (show all 630)
# Title Authors Year
1
Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin. ( 29498170 )
2019
2
fMRI Stroop and behavioral treatment for cocaine-dependence: Preliminary findings in methadone-maintained individuals. ( 30240978 )
2019
3
In Cocaine Dependence, Neural Prediction Errors During Loss Avoidance Are Increased With Cocaine Deprivation and Predict Drug Use. ( 30297162 )
2019
4
Borderline Personality Disorder With Cocaine Dependence: Impulsivity, Emotional Dysregulation and Amygdala Functional Connectivity. ( 30108525 )
2018
5
Netrin G1: its downregulation in the nucleus accumbens of cocaine-conditioned mice and genetic association in human cocaine dependence. ( 28074533 )
2018
6
Neurostimulation techniques in the treatment of cocaine dependence: A review of the literature. ( 28822321 )
2018
7
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. ( 28857070 )
2018
8
Attentional bias toward alcohol stimuli as a predictor of treatment retention in cocaine dependence and alcohol user patients. ( 29136565 )
2018
9
Drug Stroop: Mechanisms of response to computerized cognitive behavioral therapy for cocaine dependence in a randomized clinical trial. ( 29258028 )
2018
10
Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial. ( 29286595 )
2018
11
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. ( 29422497 )
2018
12
Effect of continuing care for people with cocaine dependence on criminal justice sentences. ( 29460440 )
2018
13
Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. ( 29464791 )
2018
14
Is Ayahuasca an Option for the Treatment of Crack Cocaine Dependence? ( 29608428 )
2018
15
How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. ( 29775957 )
2018
16
Dynamic network dysfunction in cocaine dependence: Graph theoretical metrics and stop signal reaction time. ( 29876265 )
2018
17
Ventral striatal dysfunction in cocaine dependence - difference mapping for subregional resting state functional connectivity. ( 29915214 )
2018
18
Symptoms of anhedonia, not depression, predict the outcome of treatment of cocaine dependence. ( 30032944 )
2018
19
Resting State Functional Connectivity of the Lateral and Medial Hypothalamus in Cocaine Dependence: An Exploratory Study. ( 30100886 )
2018
20
MiR-9, miR-153 and miR-124 are down-regulated by acute exposure to cocaine in a dopaminergic cell model and may contribute to cocaine dependence. ( 30166527 )
2018
21
Neuroimaging Metrics of Drug and Food Processing in Cocaine-Dependence, as a Function of Psychopathic Traits and Substance Use Severity. ( 30233344 )
2018
22
Modified cognitive behavioral therapy (M-CBT) for cocaine dependence: Development of treatment for cognitively impaired users and results from a Stage 1 trial. ( 30346186 )
2018
23
Altered fine motor control and manual dexterity in people with cocaine dependence: An observational study. ( 30575048 )
2018
24
Brain substrates of social decision-making in dual diagnosis: cocaine dependence and personality disorders. ( 26442666 )
2017
25
Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse. ( 27009114 )
2017
26
Effect of Continuing Care for Cocaine Dependence on HIV Sex-Risk Behaviors. ( 27224980 )
2017
27
Dissociable Effects of Cocaine Dependence on Reward Processes: The Role of Acute Cocaine and Craving. ( 27545986 )
2017
28
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2017
29
Kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27885412 )
2017
30
Reply to: kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27896378 )
2017
31
A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. ( 28190084 )
2017
32
Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection. ( 28251596 )
2017
33
Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis. ( 28350194 )
2017
34
Cocaine dependence modulates the effect of HIV infection on brain activation during intertemporal decision making. ( 28711810 )
2017
35
Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. ( 28714728 )
2017
36
Sex differences in guanfacine effects on stress-induced stroop performance in cocaine dependence. ( 28823835 )
2017
37
A Novel Therapy for cocaine dependence during abstinence: A randomized clinical trial. ( 28894547 )
2017
38
Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. ( 28984746 )
2017
39
White Matter Changes in HIV+ Women with a History of Cocaine Dependence. ( 29163330 )
2017
40
Polysomnographic measures of sleep in cocaine dependence and alcohol dependence: Implications for age-related loss of slow wave, stage 3 sleep. ( 26749502 )
2016
41
Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. ( 28051838 )
2016
42
Increased corticolimbic connectivity in cocaine dependence versus pathological gambling is associated with drug severity and emotion-related impulsivity. ( 25818325 )
2016
43
Deep Brain Stimulation for Refractory Cocaine Dependence. ( 26235303 )
2016
44
Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. ( 26484829 )
2016
45
Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. ( 26777774 )
2016
46
Cocaine-induced Psychosis and Brain-derived Neurothrophic Factor in Patients with Cocaine Dependence: Report of Two Cases. ( 26792050 )
2016
47
Neurofunctional Reward Processing Changes in Cocaine Dependence During Recovery. ( 26792441 )
2016
48
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. ( 26817621 )
2016
49
Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. ( 26826006 )
2016
50
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. ( 26948856 )
2016
Sources

Variations for Cocaine Dependence

About this section
Sources

Expression for Cocaine Dependence

About this section
Search GEO for disease gene expression data for Cocaine Dependence.
Sources

Pathways for Cocaine Dependence

About this section

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transmission across Chemical Synapses 67
Show member pathways
 12.69 CHRNA3 CHRNA5 CHRNB3 SLC6A3 SLC6A4
2
Circadian entrainment 38
Show member pathways
 12.67 CHRNA3 DRD1 DRD2 DRD3 OPRM1 SLC6A3
3
Peptide ligand-binding receptors 67
Show member pathways
 12.6 CHRNA3 CHRNA5 CHRNB3 DRD1 DRD2 DRD3
5
Monoamine GPCRs 1
Show member pathways
 11.67 DRD1 DRD2 DRD3
6
Amphetamine addiction 38
Show member pathways
 11.63 DRD1 DRD2 PDYN SLC6A3
7
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 62
Show member pathways
 11.27 CHRNA3 CHRNA5 DRD2 DRD3
8
Monoamine Transport 1
Show member pathways
 11.18 DBH SLC6A3 SLC6A4
9
Neurotransmitter Clearance In The Synaptic Cleft 67
Show member pathways
 10.91 SLC6A3 SLC6A4
10
DARPP-32 Phosphorylation 66
10.67 DRD1 DRD2 DRD3
Sources

GO Terms for Cocaine Dependence

About this section

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.96 CHRNA3 CHRNA5 CHRNB3 DRD1 DRD2 DRD3
2 synapse GO:0045202 9.86 CHRNA3 CHRNA5 CHRNB3 OPRK1
3 neuronal cell body GO:0043025 9.83 CHRNA3 OPRK1 PDYN SLC6A3
4 dendrite GO:0030425 9.83 CHRNA3 DRD2 OPRK1 OPRM1 PDYN
5 neuron projection GO:0043005 9.8 CHRNA3 CHRNA5 CHRNB3 SLC6A3 SLC6A4
6 perikaryon GO:0043204 9.69 DRD2 OPRK1 OPRM1
7 GABA-ergic synapse GO:0098982 9.67 DRD1 DRD2 DRD3
8 axon terminus GO:0043679 9.65 DRD2 OPRK1 PDYN
9 integral component of presynaptic membrane GO:0099056 9.63 DRD1 DRD2 OPRK1 OPRM1 SLC6A3 SLC6A4
10 non-motile cilium GO:0097730 9.55 DRD1 DRD2
11 acetylcholine-gated channel complex GO:0005892 9.5 CHRNA3 CHRNA5 CHRNB3
12 integral component of postsynaptic membrane GO:0099055 9.43 DRD1 DRD2 OPRK1 OPRM1 SLC6A3 SLC6A4
13 dopaminergic synapse GO:0098691 9.02 CHRNA5 CHRNB3 DRD2 DRD3 SLC6A3
14 membrane GO:0016020 10.28 CHRNA3 CHRNA5 CHRNB3 DBH DRD1 DRD2
15 integral component of membrane GO:0016021 10.2 CHRNA3 CHRNA5 CHRNB3 DBH DRD1 DRD2
16 plasma membrane GO:0005886 10.11 CHRNA3 CHRNA5 CHRNB3 DRD1 DRD2 DRD3

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.91 CHRNA3 CHRNA5 CHRNB3 DBH OPRK1 PDYN
2 neuropeptide signaling pathway GO:0007218 9.9 OPRK1 OPRM1 PDYN POMC
3 response to ethanol GO:0045471 9.89 DRD2 DRD3 OPRK1 OPRM1 SLC6A3
4 regulation of membrane potential GO:0042391 9.88 CHRNA3 CHRNA5 CHRNB3
5 memory GO:0007613 9.85 DBH DRD1 SLC6A4
6 nervous system process GO:0050877 9.83 CHRNA3 CHRNA5 CHRNB3
7 regulation of synaptic vesicle exocytosis GO:2000300 9.83 CHRNA5 CHRNB3 DRD1 DRD2
8 neuromuscular synaptic transmission GO:0007274 9.81 CHRNA3 CHRNA5 CHRNB3
9 visual learning GO:0008542 9.81 DBH DRD1 DRD2 DRD3
10 associative learning GO:0008306 9.8 DBH DRD1 DRD2
11 synaptic transmission, cholinergic GO:0007271 9.78 CHRNA3 CHRNA5 CHRNB3
12 response to amphetamine GO:0001975 9.78 DBH DRD1 DRD2 DRD3
13 dopamine receptor signaling pathway GO:0007212 9.77 DRD1 DRD2 DRD3
14 synaptic transmission, dopaminergic GO:0001963 9.76 DRD1 DRD2 DRD3
15 dopamine metabolic process GO:0042417 9.75 DRD1 DRD2 DRD3
16 positive regulation of cytokinesis GO:0032467 9.74 DRD2 DRD3
17 positive regulation of multicellular organism growth GO:0040018 9.74 DRD2 SLC6A3
18 maternal behavior GO:0042711 9.74 DBH DRD1 OPRK1
19 response to radiation GO:0009314 9.73 OPRK1 OPRM1
20 feeding behavior GO:0007631 9.73 DRD1 DRD2
21 regulation of sensory perception of pain GO:0051930 9.73 OPRK1 OPRM1
22 adult walking behavior GO:0007628 9.73 DRD1 DRD2
23 negative regulation of blood pressure GO:0045776 9.73 DRD2 DRD3
24 positive regulation of neurogenesis GO:0050769 9.73 DRD2 OPRM1
25 arachidonic acid secretion GO:0050482 9.72 DRD2 DRD3
26 eating behavior GO:0042755 9.72 OPRK1 OPRM1
27 temperature homeostasis GO:0001659 9.72 DRD1 DRD2
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.72 DRD2 DRD3
29 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3
30 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.72 DRD1 DRD3 OPRM1
31 excitatory postsynaptic potential GO:0060079 9.72 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1
32 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
33 estrous cycle GO:0044849 9.71 OPRK1 OPRM1
34 striatum development GO:0021756 9.71 DRD1 DRD2
35 grooming behavior GO:0007625 9.71 DRD1 DRD2
36 behavioral response to ethanol GO:0048149 9.71 DBH DRD2 OPRM1
37 response to morphine GO:0043278 9.71 DRD2 DRD3 OPRK1 OPRM1
38 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
39 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
40 G protein-coupled receptor internalization GO:0002031 9.7 DRD2 DRD3
41 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD2 DRD3
42 peristalsis GO:0030432 9.69 DRD1 DRD2
43 regulation of dopamine metabolic process GO:0042053 9.69 DRD1 SLC6A3
44 sensory perception GO:0007600 9.69 OPRK1 OPRM1
45 adenohypophysis development GO:0021984 9.68 DRD2 SLC6A3
46 monoamine transport GO:0015844 9.68 SLC6A3 SLC6A4
47 opioid receptor signaling pathway GO:0038003 9.68 OPRK1 OPRM1
48 dopamine catabolic process GO:0042420 9.67 DBH SLC6A3
49 behavioral response to nicotine GO:0035095 9.67 CHRNA3 CHRNA5
50 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.67 DRD1 DRD2

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.92 DRD1 DRD2 DRD3 OPRK1 OPRM1
2 ion channel activity GO:0005216 9.73 CHRNA3 CHRNA5 CHRNB3
3 drug binding GO:0008144 9.63 DRD2 DRD3 SLC6A3
4 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNA3 CHRNA5 CHRNB3
5 neuropeptide binding GO:0042923 9.57 OPRK1 OPRM1
6 G-protein alpha-subunit binding GO:0001965 9.55 DRD1 OPRM1
7 adrenergic receptor activity GO:0004935 9.54 DRD2 DRD3
8 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A3 SLC6A4
9 acetylcholine binding GO:0042166 9.5 CHRNA3 CHRNA5 CHRNB3
10 opioid receptor activity GO:0004985 9.49 OPRK1 OPRM1
11 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD2 DRD3
12 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
13 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNA3 CHRNA5 CHRNB3
14 ligand-gated ion channel activity GO:0015276 9.37 CHRNA3 CHRNA5
15 acetylcholine receptor activity GO:0015464 9.33 CHRNA3 CHRNA5 CHRNB3
16 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD1 DRD2 DRD3
17 dopamine binding GO:0035240 8.92 DRD1 DRD2 DRD3 SLC6A3
Sources

Sources for Cocaine Dependence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....